Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTR1F | P30939 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | HTR1D | P28221 | 2/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | VPS4B | O75351 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895642 | 0.87 | KMT2A (0.51) | KMT2AMEN1HTR1FHTR1BHTR1A | |
| SCHEMBL14880114 | 0.86 | HTR1B (0.65) | KMT2AMEN1HTR1BHTR1AHTR1D | |
| SCHEMBL4897652 | 0.85 | HTR1B (0.52) | KMT2AMEN1HTR1FHTR1BHTR1A | |
| SCHEMBL4895910 | 0.85 | HTR1B (0.52) | KMT2AMEN1HTR1FHTR1BHTR1A | |
| SCHEMBL4899304 | 0.85 | HTR1B (0.52) | KMT2AMEN1HTR1FHTR1BHTR1A | |
| SCHEMBL4899779 | 0.85 | SIRT1 (0.60) | KMT2AMEN1HTR1FHTR1BHTR1A | |
| SCHEMBL4903633 | 0.85 | SIRT1 (0.60) | KMT2AMEN1HTR1FHTR1BHTR1A | |
| SCHEMBL30523188 | 0.83 | KDM4E (0.63) | KMT2AMEN1KDM4EALDH1A1MAPT | |
| SCHEMBL30523189 | 0.83 | KDM4E (0.63) | KMT2AMEN1KDM4EALDH1A1MAPT | |
| SCHEMBL4728062 | 0.83 | KDM4E (0.63) | KMT2AMEN1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2021-08-19 | — | — | US | disclosed |
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | disclosed |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180271835-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2018-09-27 | — | — | US | disclosed |
| US-9895351-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY | 2016-10-20 | — | — | US | disclosed |
| EP-3078374-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9346803-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | disclosed |
| EP-2768499-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3904/4885MEN1 2723/4885HTR1F 3842/4885 |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3904/4885MEN1 2723/4885HTR1F 3842/4885 |
| US-20180271835-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3904/4885MEN1 2723/4885HTR1F 3842/4885 |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3904/4885MEN1 2723/4885HTR1F 3842/4885 |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3865/4885MEN1 2132/4885HTR1F 3739/4885 |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3904/4885MEN1 2723/4885HTR1F 3842/4885 |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | KMT2A 3904/4885MEN1 2723/4885HTR1F 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.